(Finance) – Protagonist Registerwhich shows an excellent performance, with an increase of 4.63%.
The stock was already subject to strong purchases in the morning following the announcement of an agreement signed with the British big pharmaceutical company GSK, for the exclusive marketing of two urological drugs in 21 EU countries.
The analysts of Equity they confirmed the “buy” opinion on the stock by raising the target price to 53.5 euro compared to the 45.36 of the current prices. The experts of the office of Mediobanca reiterated the “Outperform” recommendation and the target price of 50.40 euros.
By comparing the performance of the stock with the FTSEMIBon a weekly basis, it is noted that the pharmaceutical group maintains positive relative strength compared to the index, demonstrating greater appreciation by investors compared to the index itself (weekly performance +5.29%, compared to +0.34% of the main index of the Milan Stock Exchange).
Contraction for the general technical picture with the price curve forced to undergo the greater pressure of the sellers with quota insights towards 44.15 Euros. On the contrary, sudden bullish ideas could instead find resistance at 45.68. The weakening of Register it is identified by the breakout of the 5 day moving average under the 8 day longer term algorithm. The most consistent expectations are for a continuation of the negative trend towards the 43.15 area.